+44 7723 059341
Established biopharma teams bring in Z2 for focused, senior expertise: an independent view of a cell line or upstream programme, specialist input on complex formats, media or scale-up, or additional capacity at a critical point in development.
How Z2 helps
- Independent technical review of CLD and upstream programmes
- Specialist input on complex formats, media and process intensification
- Technology-transfer and comparability support across sites and CDMOs
- CMC documentation review and IND/BLA support
- Bespoke training for development teams
Investors & strategic partners
Where and how an asset is made is now part of what it is worth. Z2 provides independent CMC due diligence so red flags are found before you commit – assessing technology maturity, scalability, development risk and CMC readiness, including where an asset is manufactured.
74%
of FDA rejection letters 2020–2024 cited CMC deficiencies1
$174B
pharmaceutical CDMO market in 2025; top five hold 30%2
£2.6B
UK biotech VC in H1 20263
Where rushed timelines break
Diligence reads CMC summaries, not raw data – and few deal teams can judge whether a process can move sites.
Where Z2 helps
A data-room review of clone, process and CDMO, with a red-flag report.
Sources
- Pharmaceutical Technology. CMC and analytical gaps in CRLs, July 2026.
- Global Market Insights. Pharmaceutical CDMO market report, 2026.
- BIA / Biotech Finance. UK biotech financing Q2 2026.
